📊 PEN Key Takeaways
Is Penumbra Inc (PEN) a Good Investment?
Penumbra demonstrates solid fundamental growth with 17.5% revenue expansion and exceptional financial health characterized by zero debt and $241.3M cash. Strong free cash flow generation (19.6% FCF margin) and high gross margins (67.6%) indicate a well-managed medical device business, though low ROE (2.2%) and ROA (1.7%) suggest capital efficiency challenges requiring attention.
Penumbra Inc Key Strengths (PEN)
- Strong revenue growth of 17.5% YoY with robust 67.6% gross margin in stable medical device sector
- Exceptional balance sheet strength: zero long-term debt, $241.3M cash, 6.02x current ratio
- Excellent free cash flow generation at $73.3M (19.6% FCF margin) with healthy $87M operating cash flow
PEN Stock Risks: Penumbra Inc Investment Risks
- Low return on equity (2.2%) and return on assets (1.7%) indicate inefficient capital deployment despite profitability
- Operating margin at 10.2% is modest for medical device sector, suggesting potential pricing or cost structure pressures
- Unusual EPS spike of +1155.6% YoY may indicate prior-period distortions affecting earnings quality assessment
Key Metrics to Watch
- Operating margin expansion and capital efficiency metrics (ROE/ROA improvement)
- Revenue growth sustainability and free cash flow conversion maintenance
- Insider Form 4 filing patterns and capital allocation decisions
Penumbra Inc (PEN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.02x current ratio provides a solid financial cushion.
PEN Profit Margin, ROE & Profitability Analysis
PEN vs Healthcare Sector: How Penumbra Inc Compares
How Penumbra Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Penumbra Inc Stock Overvalued? PEN Valuation Analysis 2026
Based on fundamental analysis, Penumbra Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Penumbra Inc Balance Sheet: PEN Debt, Cash & Liquidity
PEN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Penumbra Inc's revenue has grown significantly by 88% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.32 reflects profitable operations.
PEN Revenue Growth, EPS Growth & YoY Performance
PEN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $324.1M | $32.6M | $0.82 |
| Q3 2025 | $301.0M | $11.0M | $-0.51 |
| Q2 2025 | $299.4M | $11.0M | $1.15 |
| Q1 2025 | $278.7M | $11.0M | $0.28 |
| Q3 2024 | $270.9M | $8.6M | $0.23 |
| Q2 2024 | $261.5M | $8.6M | $0.48 |
| Q1 2024 | $241.4M | $8.6M | $0.22 |
| Q3 2023 | $213.7M | $79.0K | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Penumbra Inc Dividends, Buybacks & Capital Allocation
PEN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Penumbra Inc (CIK: 0001321732)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PEN
What is the AI rating for PEN?
Penumbra Inc (PEN) has an AI grade of A with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PEN's key strengths?
Claude: Strong revenue growth of 17.5% YoY with robust 67.6% gross margin in stable medical device sector. Exceptional balance sheet strength: zero long-term debt, $241.3M cash, 6.02x current ratio.
What are the risks of investing in PEN?
Claude: Low return on equity (2.2%) and return on assets (1.7%) indicate inefficient capital deployment despite profitability. Operating margin at 10.2% is modest for medical device sector, suggesting potential pricing or cost structure pressures.
What is PEN's revenue and growth?
Penumbra Inc reported revenue of $374.8M.
Does PEN pay dividends?
Penumbra Inc does not currently pay dividends.
Where can I find PEN SEC filings?
Official SEC filings for Penumbra Inc (CIK: 0001321732) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PEN's EPS?
Penumbra Inc has a diluted EPS of $0.82.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PEN's fundamental grade?
Based on our AI fundamental analysis in May 2026, Penumbra Inc has a A grade with 78% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is PEN stock overvalued or undervalued?
Valuation metrics for PEN: ROE of 2.2% (sector avg: 15%), net margin of 8.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PEN's AI grade for 2026?
Our dual AI analysis gives Penumbra Inc a combined A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PEN's free cash flow?
Penumbra Inc's operating cash flow is $87.0M, with capital expenditures of $13.7M. FCF margin is 19.6%.
How does PEN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 8.7% (avg: 12%), ROE 2.2% (avg: 15%), current ratio 6.02 (avg: 2).